Franco Dosio is associate professor in CHIM09 Applied and Technological Pharmaceutics at Turin University since the year 2000.
Since 1980 he has coordinated a research group studying the delivery and the targeting of drugs or biologically active proteins. F.D.
since 1985 in collaboration with the Istituto Tumori di Milano (ITM) he was involved in a study of targeting of toxins with
monoclonal antibodies (immunotoxins). Later, with the ITM and the pharmaceutical company Menarini (Biosud Research) he
participated in an IMI project on the development of new ITs of clinical relevance. In 1992 he partecipate in a research program on
liposomes and immunoliposomes loaded with antitumoral drugs. In the period 1995-1997 he was a recipient of grants from
Associazione Italiana per la Ricerca sul Cancro (AIRC) for the project entitled "targeting of drugs using monoclonal antibodies and
liposomes". Then started a study on the use of nanospheres or immuno-nanospheres as antitumoural agents. In the period 1996-2000
he was involved in clinical trials for the development of new formulation of the anticancer drug paclitaxel (both in injectable oily
solution and in albumin nanoparticles)administered into hepatic artery for the treatment of hepatic cancer. These trials were
performed in ITM and hospitals. Since 2001 he is in the board of Italian chapter of Controlled Release Society. Prof. Dosio is author
of 46 articles published in international journals, reviews, 2 patents and several posters to congress.